relugolix + ARPI

Phase 2Small molecule

UUniversity of Utah

relugolix + ARPI is one of 34 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Metastatic Hormone-Sensitive Prostate Cancer (mhspc)Recruiting

Prostate CancerPhase 2

Active, not recruiting

Metastatic Hormone-Sensitive Prostate Cancer (mhspc)Phase 2

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

relugolix + ARPI

UUniversity of Utah

Phase 2

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Ifex

BBaxter Healthcare Corporation

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 2Recruiting

Metastatic Hormone-Sensitive Prostate Cancer (mhspc)

NCT07216248

Clinical

Trials by Indication[1]

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1 trial

A Phase II Randomized, Decentralized, De-escalation Study in Patients With Metastatic Hormone-Sensitive Prostate Cancer Achieving Optimal PSA Response (OPTIMAS)

Recruiting·UUniversity of Utah·Phase 2·NCT07216248·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for relugolix + ARPI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — relugolix + ARPI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for relugolix + ARPI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Utah company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Utah

relugolix + ARPI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1 trial

References

Drug Info

Quick Facts

Related News